摘要
Future Medicinal ChemistryVol. 14, No. 20 EditorialThe key new techniques in the medicinal chemist’s toolkit to prioritize solubility during drug designPooja Sahu & Rajnish KumarPooja SahuRoyal College of Pharmacy, Raipur, Chhattisgarh, IndiaSearch for more papers by this author & Rajnish Kumar *Author for correspondence: E-mail Address: rajnish.phe@iitbhu.ac.inhttps://orcid.org/0000-0002-7021-6996Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (B.H.U.), Varanasi, 221005, U.P., IndiaSearch for more papers by this authorPublished Online:27 Sep 2022https://doi.org/10.4155/fmc-2022-0225AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: bioisosterism and prodrug approachescrystal packing disruptionheterocyclic modificationssolubilitystructural modificationReference1. Van de Waterbeemd H, Smith DA, Beaumont K, Walker DK. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44(9), 1313–1333 (2001).Crossref, Medline, Google Scholar2. Li D, Paul VF, Takashi M. Bridging solubility between drug discovery and development. Drug Discov.Today 17(9-10), 486–495 (2012).Crossref, Medline, Google Scholar3. Schneider G. Automating drug discovery. Nat Rev Drug Discov. 17, 97–113 (2018).Crossref, Medline, CAS, Google Scholar4. Das B, Baidya ATK, Mathew A et al. Structural modification aimed for improving solubility of lead compounds in early phase drug discovery. Bioorg. Med. Chem. 56, 116614 (2022).Crossref, Medline, CAS, Google Scholar5. Ishikawa M, Hashimoto Y. Improving the water-solubility of compounds by molecular modification to disrupt crystal packing. The Practice of Medicinal Chemistry (4th Edition). Wermuth CGAldous DRaboisson PRognan D (Eds.). Academic Press, London, UK, 747–765 (2015).Crossref, Google Scholar6. Charalabidis A, Sfouni M, Bergström C, Macheras P. The biopharmaceutics classification system (BCS) and the biopharmaceutics drug disposition classification system (BDDCS): beyond guidelines. Int. J. Pharm. 566, 264–281 (2019).Crossref, Medline, CAS, Google Scholar7. Saal C, Petereit AC. Optimizing solubility: kinetic versus thermodynamic solubility temptations and risks. Eur. J. Pharm. Sci. 47, 589–595 (2012).Crossref, Medline, CAS, Google Scholar8. Testa B, Crivori P, Reist M, Carrupt PA. The influence of lipophilicity on the pharmacokinetic behavior of drugs: Concepts and examples. Perspectives in Drug Discovery and Design 19(1), 179–211 (2000).Crossref, Google Scholar9. Naylor MR, Ly AM, Handford MJ et al. Lipophilic permeability efficiency (LPE) reconciles the opposing roles of lipophilicity in membrane permeability and aqueous solubility. J. Med. Chem. 61, 11169–11182 (2018).Crossref, Medline, CAS, Google Scholar10. Lu Y, Li C-M, Wang Z. Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents. J. Med. Chem. 54, 4678–4693 (2011).Crossref, Medline, CAS, Google Scholar11. Kuhn B, Mohr P, Stahl M. Intramolecular hydrogen bonding in medicinal chemistry. J. Med. Chem. 53, 2601–2611 (2010).Crossref, Medline, CAS, Google Scholar12. Etter MC. Encoding and decoding hydrogen-bond patterns of organic compounds. Acc. Chem. Res. 23, 120–126 (1990).Crossref, CAS, Google Scholar13. Pinal R. Effect of molecular symmetry on melting temperature and solubility. Org. Biomol. Chem. 2, 2692–2699 (2004).Crossref, Medline, CAS, Google Scholar14. Nikam SS, Cordon JJ, Ortwine DF et al. Design and synthesis of novel quinoxaline-2, 3-dione AMPA/GlyN receptor antagonists: amino acid derivatives. J. Med. Chem. 42, 2266–2271 (1999).Crossref, Medline, CAS, Google Scholar15. Fujita Y, Yonehara M, Tetsuhashi M et al. β-Naphthoflavone analogs as potent and soluble aryl hydrocarbon receptor agonists: Improvement of solubility by disruption of molecular planarity. Bioorg Med Chem. 18, 1194–1203 (2010).Crossref, Medline, CAS, Google Scholar16. Bachovchin KA, Sharma A, Bag S et al. Improvement of aqueous solubility of lapatinib-derived analogues: identification of a quinolinimine lead for human African trypanosomiasis drug development. J. Med. Chem. 62, 665–687 (2018).Crossref, Google Scholar17. Lewin G, Maciuk A, Moncomble AI, Cornard J-P. Enhancement of the water solubility of flavone glycosides by disruption of molecular planarity of the aglycone moiety. J. Nat. Prod. 76, 8–12 (2013).Crossref, Medline, CAS, Google Scholar18. Kumari S, Carmona AV, Tiwari AK, Trippier PC. Amide bond bioisosteres: strategies, synthesis, and successes. J. Med. Chem. 63, 12290–12358 (2020).Crossref, Medline, CAS, Google Scholar19. Rubio-Ruiz B, Pérez-López AM, Sebastián V, Unciti-Broceta A. A minimally masked inactive prodrug of panobinostat that is bioorthogonally activated by gold chemistry. Bioorg. Med. Chem. 41, 116217–116223 (2021).Crossref, Medline, CAS, Google Scholar20. Jornada DH, dos Santos Fernandes GF, Chiba DE et al. The prodrug approach: a successful tool for improving drug solubility. Molecules 21, 42–73 (2016).Crossref, Google ScholarFiguresReferencesRelatedDetails Vol. 14, No. 20 Follow us on social media for the latest updates Metrics Downloaded 52 times History Received 11 September 2022 Accepted 15 September 2022 Published online 27 September 2022 Published in print October 2022 Information© 2022 Newlands PressKeywordsbioisosterism and prodrug approachescrystal packing disruptionheterocyclic modificationssolubilitystructural modificationFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download